CervoMed Inc.
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more
CervoMed Inc. (CRVO) - Net Assets
Latest net assets as of September 2025: $26.01 Million USD
Based on the latest financial reports, CervoMed Inc. (CRVO) has net assets worth $26.01 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.61 Million) and total liabilities ($4.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.01 Million |
| % of Total Assets | 84.97% |
| Annual Growth Rate | 7.85% |
| 5-Year Change | 57.98% |
| 10-Year Change | N/A |
| Growth Volatility | 20416.91 |
CervoMed Inc. - Net Assets Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CervoMed Inc. (1998–2024)
The table below shows the annual net assets of CervoMed Inc. from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $39.20 Million | +431.43% |
| 2023-12-31 | $7.38 Million | +181.98% |
| 2022-12-31 | $-9.00 Million | -125.77% |
| 2021-12-31 | $34.91 Million | +40.69% |
| 2020-12-31 | $24.81 Million | +23.24% |
| 2019-12-31 | $20.13 Million | +28.97% |
| 2018-12-31 | $15.61 Million | -26.46% |
| 2017-12-31 | $21.23 Million | +131.15% |
| 2016-12-31 | $9.18 Million | +22166.37% |
| 2015-12-31 | $-41.62K | -100.11% |
| 2014-12-31 | $38.17 Million | +490.33% |
| 2013-12-31 | $6.47 Million | +135.12% |
| 2012-12-31 | $-18.41 Million | -15.03% |
| 2011-12-31 | $-16.00 Million | -79225.35% |
| 2010-12-31 | $20.22K | -95.90% |
| 2009-12-31 | $493.60K | +12.44% |
| 2008-12-31 | $438.99K | +148.46% |
| 2007-12-31 | $-905.93K | -132.69% |
| 1999-12-31 | $2.77 Million | -49.62% |
| 1998-12-31 | $5.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CervoMed Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6893148400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.70K | 0.02% |
| Other Comprehensive Income | $56.20K | 0.14% |
| Other Components | $109.87 Million | 280.26% |
| Total Equity | $39.20 Million | 100.00% |
CervoMed Inc. Competitors by Market Cap
The table below lists competitors of CervoMed Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kobay Tech Bhd
KLSE:6971
|
$24.88 Million |
|
EuroDry Ltd
NASDAQ:EDRY
|
$24.88 Million |
|
Sharp Therapeutics Corp.
V:SHRX
|
$24.89 Million |
|
New Peoples Bankshares Inc
PINK:NWPP
|
$24.89 Million |
|
First Phosphate Corp.
OTCQB:FRSPF
|
$24.87 Million |
|
Honyi International Company Limited
TWO:4530
|
$24.87 Million |
|
E& Corporation CO. LTD
KQ:066980
|
$24.87 Million |
|
Hexagon Purus ASA
PINK:HPURF
|
$24.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CervoMed Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,376,774 to 39,202,328, a change of 31,825,554 (431.4%).
- Net loss of 16,290,695 reduced equity.
- New share issuances of 46,398,606 increased equity.
- Other comprehensive income increased equity by 10,028,718.
- Other factors decreased equity by 8,311,075.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.29 Million | -41.56% |
| Share Issuances | $46.40 Million | +118.36% |
| Other Comprehensive Income | $10.03 Million | +25.58% |
| Other Changes | $-8.31 Million | -21.2% |
| Total Change | $- | 431.43% |
Book Value vs Market Value Analysis
This analysis compares CervoMed Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.93x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $-862390.91 | $4.53 | x |
| 2006-12-31 | $-1299627.27 | $4.53 | x |
| 2007-12-31 | $-20864.35 | $4.53 | x |
| 2008-12-31 | $8958.98 | $4.53 | x |
| 2009-12-31 | $9625.49 | $4.53 | x |
| 2010-12-31 | $361.13 | $4.53 | x |
| 2011-12-31 | $-205542.12 | $4.53 | x |
| 2012-12-31 | $-232750.13 | $4.53 | x |
| 2013-12-31 | $27454.87 | $4.53 | x |
| 2014-12-31 | $30028.03 | $4.53 | x |
| 2015-12-31 | $-178.73 | $4.53 | x |
| 2016-12-31 | $1009.86 | $4.53 | x |
| 2017-12-31 | $1872.46 | $4.53 | x |
| 2018-12-31 | $361.13 | $4.53 | x |
| 2019-12-31 | $225.17 | $4.53 | x |
| 2020-12-31 | $34.57 | $4.53 | x |
| 2021-12-31 | $26.81 | $4.53 | x |
| 2022-12-31 | $-17.37 | $4.53 | x |
| 2023-12-31 | $2.77 | $4.53 | x |
| 2024-12-31 | $4.86 | $4.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CervoMed Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -167.29%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.10x
- Recent ROE (-41.56%) is above the historical average (-1985.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 3.64% | 0.72% | 1.51x | 3.36x | $-350.00K |
| 1999 | -290.88% | -29.92% | 1.21x | 8.01x | $-8.34 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-85.38K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.80K |
| 2007 | 0.00% | -863.45% | 0.05x | 0.00x | $-2.58 Million |
| 2008 | -476.78% | -5207.89% | 0.01x | 12.22x | $-2.14 Million |
| 2009 | -689.03% | 0.00% | 0.00x | 8.68x | $-3.45 Million |
| 2010 | -41586.31% | -20926.12% | 0.01x | 275.70x | $-8.41 Million |
| 2011 | 0.00% | -3967.91% | 0.16x | 0.00x | $-21.03 Million |
| 2012 | 0.00% | -1833.97% | 0.15x | 0.00x | $-5.03 Million |
| 2013 | -38.15% | -3438.12% | 0.00x | 2.84x | $-3.11 Million |
| 2014 | -37.61% | 0.00% | 0.00x | 1.12x | $-18.17 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.71 Million |
| 2016 | -196.38% | 0.00% | 0.00x | 1.90x | $-18.96 Million |
| 2017 | -6.43% | 0.00% | 0.00x | 1.23x | $-3.49 Million |
| 2018 | -117.67% | 0.00% | 0.00x | 1.17x | $-19.93 Million |
| 2019 | -58.60% | 0.00% | 0.00x | 1.21x | $-13.81 Million |
| 2020 | -57.16% | 0.00% | 0.00x | 1.12x | $-16.67 Million |
| 2021 | -69.02% | 0.00% | 0.00x | 1.08x | $-27.59 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.69 Million |
| 2023 | -29.44% | -30.40% | 0.72x | 1.35x | $-2.91 Million |
| 2024 | -41.56% | -167.29% | 0.23x | 1.10x | $-20.21 Million |
Industry Comparison
This section compares CervoMed Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CervoMed Inc. (CRVO) | $26.01 Million | 3.64% | 0.18x | $24.88 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |